EBITDA: Income before interest, taxes, depreciation and amortization.
Madrigal Pharmaceuticals, Inc. (MDGL) had EBITDA of $-91.48M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$311.34M |
|
$-94.39M |
|
$26.85M |
|
$284.49M |
|
$404.06M |
|
$-92.72M |
|
$-1.67M |
|
$-94.39M |
|
$-94.39M |
|
$-94.39M |
|
$-94.39M |
|
$-94.39M |
|
$-94.39M |
|
$-92.72M |
|
|
EBITDA |
$-91.48M |
29.03M |
|
29.03M |
|
$-3.25 |
|
$-3.25 |
|
| Balance Sheet Financials | |
$1.18B |
|
$8.04M |
|
$45.02M |
|
$1.23B |
|
$338.26M |
|
$340.33M |
|
$345.61M |
|
$683.87M |
|
$543.45M |
|
$536.17M |
|
$543.45M |
|
23.04M |
|
| Cash Flow Statement Financials | |
$-167.44M |
|
$192.19M |
|
$2.33M |
|
$203.78M |
|
$232.19M |
|
$28.41M |
|
$34.02M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.50 |
|
-- |
|
-- |
|
0.39 |
|
0.63 |
|
91.38% |
|
-29.78% |
|
-29.78% |
|
-- |
|
-30.32% |
|
-30.32% |
|
$-171.28M |
|
-- |
|
-- |
|
-- |
|
0.25 |
|
0.24 |
|
1.66 |
|
54.16 |
|
-17.37% |
|
-17.60% |
|
-7.69% |
|
-10.68% |
|
$23.59 |
|
$-5.90 |
|
$-5.77 |
|